Related Experiment Videos
PPARs and LXRs: atherosclerosis goes nuclear
Grant D Barish1, Ronald M Evans
1Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, PO Box 85800, San Diego, CA 92186-5800, USA.
Trends in Endocrinology and Metabolism: TEM
|April 28, 2004
Summary
New therapeutics targeting metabolic and inflammatory factors are needed for atherosclerosis, a leading cause of death. Peroxisome proliferator-activated receptors and liver X receptors show potential for cardiovascular disease treatment.
Area of Science:
- Cardiovascular Science
- Metabolic Disease
- Inflammation Biology
Background:
- Atherosclerosis is a primary cause of mortality globally.
- Effective therapeutics targeting its pathogenesis are crucial.
- Metabolic and inflammatory pathways are key contributors to atherosclerosis.
Purpose of the Study:
- To explore the therapeutic potential of nuclear receptors in cardiovascular disease.
- To investigate the roles of Peroxisome proliferator-activated receptors (PPARs) and Liver X receptors (LXRs) in atherosclerosis.
- To highlight the significance of synthetic ligands for PPARs and LXRs.
Main Methods:
- Review of current understanding of PPAR and LXR functions in physiology.
- Analysis of the development and characteristics of high-affinity synthetic ligands.
- Examination of the modulation of metabolic and inflammatory factors by PPARs and LXRs.
Main Results:
- PPARs and LXRs are lipid-activated nuclear receptors.
- These receptors regulate systemic glucose and lipid metabolism.
- They also modulate inflammation within the vascular wall.
Conclusions:
- PPARs and LXRs represent promising therapeutic targets for cardiovascular disease.
- Synthetic ligands offer a potential strategy for treating atherosclerosis.
- Further research into PPAR and LXR modulation is warranted for cardiovascular health.